Welcome to our dedicated page for Firefly Neuroscience news (Ticker: AIFF), a resource for investors and traders seeking the latest updates and insights on Firefly Neuroscience stock.
Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence company in the technology sector that develops EEG- and ERP-based brain analytics platforms for neurological and mental health applications. The Firefly Neuroscience news feed on Stock Titan aggregates company announcements, research updates, financial results, and partnership news that reflect how the business is progressing with commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) platform and related technologies.
Investors and followers of AIFF can use this page to review Firefly’s periodic disclosures about revenue trends, EEG/ERP scan volumes, operating expenses, and other financial metrics reported in its earnings releases. Recent news has highlighted revenue growth, reduced operating expenses, and the impact of the company’s acquisition of Evoke Neuroscience, Inc., which expanded Firefly’s EEG/ERP database, patent portfolio, and commercial user base.
Beyond financial reporting, Firefly frequently issues news about scientific and clinical collaborations. Examples include its engagement with the Institute of Human Genetics at Heidelberg University Hospital on EEG biomarker research for 15q13.3 copy number variants, a collaboration with Hemostemix Inc. to use BNA as an exploratory endpoint in a vascular dementia clinical trial, and research demonstrating combined EEG/ERP and volumetric MRI approaches to differentiate stages of cognitive impairment in Alzheimer’s patients.
Company updates also cover technology developments and commercial partnerships, such as the launch of the CLEAR preprocessing platform built on NVIDIA GPU acceleration and a partnership with HealingMaps and Advanced Behavioral Strategies to offer cognitive electrophysiology analytics to a large network of ketamine, psilocybin, and TMS clinics across North America. By monitoring this news page, readers can track how Firefly advances its AI-driven brain analytics, expands its data assets, and pursues its stated goal of building an EEG/ERP-based foundation model of the human brain.
Firefly Neuroscience (NASDAQ: AIFF) announced that its Board of Directors has granted 557,885 restricted shares as an inducement grant to David Johnson, the Company's Executive Chairman. The shares will vest in two equal installments at six and twelve months from the grant date, contingent on Johnson's continued service. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and falls under the Company's 2024 Long-Term Incentive Plan.
Firefly Neuroscience (NASDAQ: AIFF) has announced a collaboration with Bright Minds Biosciences to analyze data from Bright Minds' positive Phase 1 study using Firefly's AI-powered BNA™ technology. The study focused on Bright Minds' lead compound, BMB-101, and utilized EEG headsets provided by Firefly's partner, Zeto.
The qEEG data analysis demonstrated positive results, with EEG recordings taken at multiple timepoints during the study. Firefly's advanced EEG analysis platform was used to process the data. Jon Olsen, CEO of Firefly, highlighted the value of their AI platform for clinical studies, while Ian McDonald, CEO of Bright Minds, stated that the results validate their approach and indicate that BMB-101 is achieving brain penetration as predicted.
With the completion of this Phase 1 study, BMB-101 is now considered a Phase 2 ready asset, and Bright Minds plans to move forward with an investigative new drug submission.
Firefly Neuroscience (NASDAQ: AIFF) announced that its FDA-510(k) cleared Brain Network Analytics (BNA™) biomarker discovery AI platform will support Arrivo Bioventures' Phase 1 exploratory study of SP-624, a first-in-class SIRT6 activator for major depressive disorder (MDD). The study will evaluate SP-624's impact on neurological pathways and cognitive domains in healthy volunteers and MDD patients.
SP-624 is also being studied in a large Phase 2b trial, focusing on efficacy in females. In a previous Phase 2 study, SP-624 showed statistically significant improvement versus placebo in female subjects with MDD, but not in males. Firefly's BNA™ technology aims to identify target engagement and biomarkers for future neurological studies, potentially addressing the unmet medical need in women's mental health.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on improving brain health outcomes, has announced its participation in two upcoming investor conferences in October 2024:
1. Maxim Healthcare Virtual Summit: October 15-17, 2024
- Fireside chat with Maxim Analyst Allen Klee
- Presentation on Thursday, October 17th at 10:00 a.m. ET
2. ThinkEquity Conference: October 30, 2024
- Location: Mandarin Oriental Hotel, New York, NY
- Presentation on Wednesday, October 30th at 11:00 a.m. ET
Webcasts for both events will be available on the company's investor relations website. Investors can schedule one-on-one meetings with management through conference representatives or by contacting KCSA Strategic Communications.
Firefly Neuroscience (NASDAQ: AIFF) has announced advancements in its AI-powered Brain Network Analytics (BNA™) technology following successful research collaborations with Takeda and Novartis. The collaborations demonstrate the value of Firefly's AI-based technology in providing objective measures for neuroscience drug development.
CEO Jon Olsen highlighted that BNA™ technology enables pharmaceutical companies to enhance trial design, accelerate drug candidate advancement, and improve clinical outcomes. The technology offers tools for improved patient and dose selection, potentially reducing costs and development time in CNS drug development.
Firefly aims to expand partnerships with neuroscience pharmaceutical companies, leveraging its unique database and technology. The company believes that electrophysiology-based biomarkers like BNA represent a significant opportunity for neuroscience drug development, especially in addressing concerns about the high cost of new drugs and identifying patients most likely to benefit from them.
Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership with Zeto, a leading EEG brain monitoring technology innovator. The collaboration will integrate Firefly's proprietary Brain Network Analytics (BNA™) technology with Zeto's FDA-cleared EEG platform, currently used in over 200 hospitals and neurology offices nationwide. Firefly will act as a non-exclusive distributor of Zeto's EEG headset devices, cloud platform, and services, expanding its accessibility to healthcare providers.
This partnership aims to offer deeper insights into neurological conditions, potentially improving patient outcomes. Zeto's FDA-cleared EEG headsets (WR19 and Zeto ONE) are designed for various clinical settings, including ICUs, EDs, hospitals, offices, and homes. The integration with Firefly's BNA™ platform is expected to enable more precise analysis and expanded use of EEG technology, optimizing diagnostics for a wide range of neurological disorders.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on brain health solutions, has appointed Dr. Stella Vnook to its Board of Directors, effective August 19, 2024. Dr. Vnook, with over 25 years of experience in pharmaceuticals and biotechnology, will serve as Chairperson of the Nominating Committee. She brings expertise as a pharmaceutical executive, entrepreneur, and founder of multiple biotech companies.
Currently, Dr. Vnook is the CEO of Likarda Biotech and Founder and Chair of OralBiolife Biosciences. She also advises several startups and supports innovation at various universities. Her background includes roles at Merck, Jazz Pharmaceuticals, and Catalant. Dr. Vnook holds multiple science degrees, an MBA in Global Marketing, and a Doctorate in Public Health focused on Health Economics.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on improving brain health outcomes, announced that CEO Jon Olsen will present at the H.C. Wainwright's 26th Annual Global Investment Conference on September 11, 2024, at 1:30 p.m. ET. The event will be held at the Lotte New York Palace Hotel.
Olsen will discuss recent corporate milestones, including the merger with WaveDancer and Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) platform. This innovative technology aims to support clinicians in diagnosing and optimizing patient care for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Investors can schedule one-on-one meetings with Olsen and Chief Medical Officer Dr. Samer Kaba. A webcast of the presentation will be available, with a 90-day replay accessible on the company's website.
Firefly Neuroscience (NASDAQ: AIFF), an AI-driven brain health company, has announced a shareholder update call scheduled for September 4, 2024, at 5:00 PM EST. The company, which focuses on developing innovative neuroscientific solutions for mental illnesses and neurological disorders, will provide investors with the latest information about its operations and progress.
Shareholders and interested parties can register for the webinar through the provided Zoom link. This update call presents an opportunity for investors to gain insights into Firefly's advancements in AI technology applied to brain health and its potential impact on patient outcomes.
Firefly Neuroscience (NASDAQ: AIFF) has formed a strategic partnership with Neurology Consultants of Dallas (NCD) to enhance early detection and management of cognitive disorders. NCD will integrate Firefly's Brain Network Analytics (BNA) technology into its patient protocols and conduct clinical studies to identify biomarkers for predicting dementia onset. This collaboration aims to optimize patient care pathways and improve outcomes for those suffering from cognitive decline.
The partnership highlights the clinical value of BNA technology in providing diagnostic insights and trending analysis for conditions such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. By establishing cognitive baselines, healthcare providers can more accurately track changes and promote early detection. This integration is expected to enhance neurology testing for millions of U.S. patients by encouraging widespread adoption of advanced diagnostic tools.